Annual Total Expenses
$167.99 M
-$4.45 M-2.58%
December 31, 2023
Summary
- As of February 7, 2025, PHAT annual total expenses is $167.99 million, with the most recent change of -$4.45 million (-2.58%) on December 31, 2023.
- During the last 3 years, PHAT annual total expenses has risen by +$42.33 million (+33.68%).
- PHAT annual total expenses is now -2.58% below its all-time high of $172.44 million, reached on December 31, 2022.
Performance
PHAT Total Expenses Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly Total Expenses
$87.15 M
+$2.52 M+2.98%
September 30, 2024
Summary
- As of February 7, 2025, PHAT quarterly total expenses is $87.15 million, with the most recent change of +$2.52 million (+2.98%) on September 30, 2024.
- Over the past year, PHAT quarterly total expenses has increased by +$2.52 million (+2.98%).
- PHAT quarterly total expenses is now at all-time high.
Performance
PHAT Quarterly Total Expenses Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Total Expenses Formula
Total Expenses = Cost of Goods Sold + Operating Expenses + Non Operating Expenses
PHAT Total Expenses Trends
PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
---|---|---|
1 y1 year | -2.6% | +3.0% |
3 y3 years | +33.7% | +86.8% |
5 y5 years | +10000.0% | +86.8% |
PHAT Total Expenses Highs & Lows
PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
---|---|---|---|---|---|
3 y | 3-year | -2.6% | +24.4% | at high | +189.8% |
5 y | 5-year | -2.6% | +58.2% | at high | +455.3% |
alltime | all time | -2.6% | >+9999.0% | at high | >+9999.0% |
Phathom Pharmaceuticals Total Expenses History
Date | Annual | Quarterly |
---|---|---|
Sep 2024 | - | $87.15 M(+3.0%) |
Jun 2024 | - | $84.62 M(+17.8%) |
Mar 2024 | - | $71.87 M(+1.9%) |
Dec 2023 | $167.99 M(-2.6%) | $70.56 M(+97.9%) |
Sep 2023 | - | $35.66 M(+12.5%) |
Jun 2023 | - | $31.70 M(+5.4%) |
Mar 2023 | - | $30.08 M(-35.5%) |
Dec 2022 | $172.44 M(+27.7%) | $46.64 M(+9.7%) |
Sep 2022 | - | $42.53 M(-6.2%) |
Jun 2022 | - | $45.36 M(+19.7%) |
Mar 2022 | - | $37.91 M(+14.7%) |
Dec 2021 | $135.08 M | $33.04 M(-0.3%) |
Date | Annual | Quarterly |
---|---|---|
Sep 2021 | - | $33.14 M(-6.2%) |
Jun 2021 | - | $35.32 M(+5.2%) |
Mar 2021 | - | $33.58 M(-36.0%) |
Dec 2020 | $125.67 M(+18.3%) | $52.44 M(+59.7%) |
Sep 2020 | - | $32.83 M(+64.0%) |
Jun 2020 | - | $20.02 M(-1.7%) |
Mar 2020 | - | $20.38 M(+29.8%) |
Dec 2019 | $106.22 M(+8570.6%) | $15.69 M(+149.8%) |
Sep 2019 | - | $6.28 M(-92.4%) |
Jun 2019 | - | $83.01 M(+6671.1%) |
Mar 2019 | - | $1.23 M(+171.8%) |
Dec 2018 | $1.23 M | $451.00 K(+68.3%) |
Sep 2018 | - | $268.00 K |
FAQ
- What is Phathom Pharmaceuticals annual total expenses?
- What is the all time high annual total expenses for Phathom Pharmaceuticals?
- What is Phathom Pharmaceuticals annual total expenses year-on-year change?
- What is Phathom Pharmaceuticals quarterly total expenses?
- What is the all time high quarterly total expenses for Phathom Pharmaceuticals?
- What is Phathom Pharmaceuticals quarterly total expenses year-on-year change?
What is Phathom Pharmaceuticals annual total expenses?
The current annual total expenses of PHAT is $167.99 M
What is the all time high annual total expenses for Phathom Pharmaceuticals?
Phathom Pharmaceuticals all-time high annual total expenses is $172.44 M
What is Phathom Pharmaceuticals annual total expenses year-on-year change?
Over the past year, PHAT annual total expenses has changed by -$4.45 M (-2.58%)
What is Phathom Pharmaceuticals quarterly total expenses?
The current quarterly total expenses of PHAT is $87.15 M
What is the all time high quarterly total expenses for Phathom Pharmaceuticals?
Phathom Pharmaceuticals all-time high quarterly total expenses is $87.15 M
What is Phathom Pharmaceuticals quarterly total expenses year-on-year change?
Over the past year, PHAT quarterly total expenses has changed by +$2.52 M (+2.98%)